

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM761067

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
SLR INVESTMENT CORP. (f/k/a SOLAR CAPITAL LTD.)		10/13/2022	Corporation: MARYLAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	SCPHARMACEUTICALS INC.		
<b>Street Address:</b>	2400 District Avenue, Suite 310		
<b>City:</b>	Burlington		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	01803		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5351975	SCPHARMACEUTICALS	
<b>Registration Number:</b>	4851675	SCPHARMACEUTICALS	
<b>Registration Number:</b>	5287573	FUROSCIX	
<b>Registration Number:</b>	5291840	SC2WEAR	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2122919868		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	(212) 558-4229		
<b>Email:</b>	demarcor@sullcrom.com, nguyenb@sullcrom.com		
<b>Correspondent Name:</b>	Raffaele A. DeMarco		
<b>Address Line 1:</b>	125 Broad Street		
<b>Address Line 2:</b>	Sullivan & Cromwell LLP		
<b>Address Line 4:</b>	New York, NEW YORK 10004-2498		
<b>ATTORNEY DOCKET NUMBER:</b>	018392.00119 (RAD)		
<b>NAME OF SUBMITTER:</b>	RAFFAELE A. DEMARCO		
<b>SIGNATURE:</b>	/RAFFAELE A. DEMARCO/		
<b>DATE SIGNED:</b>	10/13/2022		
<b>Total Attachments: 7</b>			

OP \$115.00 5351975

source=SLR - scPharma - IPSA Release [Trademark] [Executed](136561154.1)#page1.tif  
source=SLR - scPharma - IPSA Release [Trademark] [Executed](136561154.1)#page2.tif  
source=SLR - scPharma - IPSA Release [Trademark] [Executed](136561154.1)#page3.tif  
source=SLR - scPharma - IPSA Release [Trademark] [Executed](136561154.1)#page4.tif  
source=SLR - scPharma - IPSA Release [Trademark] [Executed](136561154.1)#page5.tif  
source=SLR - scPharma - IPSA Release [Trademark] [Executed](136561154.1)#page6.tif  
source=SLR - scPharma - IPSA Release [Trademark] [Executed](136561154.1)#page7.tif

TERMINATION AND RELEASE OF  
INTELLECTUAL PROPERTY SECURITY AGREEMENT

This TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “**Termination**”), dated as of October 13, 2022, is executed by SLR INVESTMENT CORP. (f/k/a SOLAR CAPITAL LTD.) (“**Agent**”), in favor of SCPHARMACEUTICALS INC., a Delaware corporation (the “**Grantor**”). All capitalized terms used in this Termination and not otherwise defined herein, shall have the respective meanings given to such terms in the IPSA (defined below).

RECITALS

A. Pursuant to that certain Intellectual Property Security Agreement, dated as of September 17, 2019 (as amended, restated, amended and restated or modified from time to time, the “**IPSA**”), by and between Grantor and Agent, Grantor granted to Agent a security interest in the IP Collateral (defined below).

B. The IPSA was recorded with the trademark division of the United States Patent and Trademark Office on September 17, 2019, at Reel/Frame 6746/0794, to evidence the security interest granted under the IPSA.

C. Agent agrees to execute this Termination in order to evidence the termination and release of its security interest in the IP Collateral specified below.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Agent hereby agrees as follows:

(a) Agent expressly terminates and releases and reassigns to Grantor, without warranty or recourse, any and all of Agent’s right, title and interest in, to and under Grantor’s intellectual property, including, without limitation, the following (collectively, the “**IP Collateral**”):

(i) any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation the copyrights described in Exhibit A attached hereto (collectively, the “**Copyrights**”);

(ii) any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(iii) any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(iv) any and all trademark and service mark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation the trademarks described in Exhibit B attached hereto (collectively, the “**Trademarks**”);

(v) any and all patents, patent applications and like protections including without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination

certificates, utility models, and continuations-in-part of the same, including without limitation the patents described in Exhibit C attached hereto (collectively, the “**Patents**”);

(vi) any and all mask works or similar rights available for the protection of semiconductor chips or other products (collectively, the “**Mask Works**”);

(vii) any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(viii) any and all licenses or other rights to use any of the Copyrights, Patents, Trademarks or Mask Works, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(ix) any and all amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(x) any and all proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.


(b) Agent represents and warrants that it has the full power and authority to execute this Termination.

(c) Agent authorizes and requests the patent and trademark divisions of the United States Patent and Trademark Office, and the United States Copyright Office, to record this Termination.

*[Signature Page Follows]*

IN WITNESS WHEREOF, Agent has executed and delivered this Termination as of the day and year first above written.

**SLR INVESTMENT CORP. (f/k/a SOLAR  
CAPITAL LTD.), as Agent**

By   
Name: Anthony Storino  
Title: Authorized Signatory

*[Termination and Release of Intellectual Property Security Agreement]*

**TRADEMARK  
REEL: 007867 FRAME: 0930**

EXHIBIT A  
COPYRIGHTS

None.

EXHIBIT B  
TRADEMARKS

MARK	CLASS	REGISTRATION NO.	COUNTRY
scPharmaceuticals	10	5351975	US
scPharmaceuticals	5	4851675	US
scPharmaceuticals	5, 10	1346216	WIPO
scPharmaceuticals	5, 10	1346216	EUROPE based on WIPO registration
FUROSCIX	10	5287573	US
FUROSCIX	5	1337899	WIPO
FUROSCIX	5	1337899	EUROPE based on WIPO registration
sc2Wear	10	5291840	US
sc2Wear	10	1340388	WIPO
sc2Wear	10	1340388	EUROPE based on WIPO registration

EXHIBIT C

PATENTS

<b>Goodwin Docket No.</b>	<b>Country</b>	<b>Application No.</b>	<b>Patent No.</b>
SPM-002AU	Australia	2014248164	
SPM-002BR	Brazil	BR112015025204-4	
SPM-002CA	Canada	2,908,935	
SPM-002CN	China, People's Republic of	201480031207.3	
SPM-002EP	Europe	14778339.3	
SPM-002HK	Hong Kong	16109253.5	
SPM-002IN	India	9291/DELNP/2015	
SPM-002IL	Israel	241917	
SPM-002JP	Japan	2016-506607	6,415,535
SPM-002JPD1	Japan	2018-187299	
SPM-002KR	Korea, Republic of	2015-7031677	
SPM-002MX	Mexico	MX/a/2015/014064	
SPM-002SG	Singapore	11201508251R	11201508251R
SPM-002SGD1	Singapore	10201709388Q	
SPM-002ZA	South Africa	2015/07320	
SPM-002	U.S.	14/781,706	9,884,039
SPM-002D1	U.S.	15/877,865	10,272,064
SPM-002D1C1	U.S.	16/295,085	
SPM-004PR	U.S.	62/799,215	



EXHIBIT D  
MASK WORKS

None.